The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA
Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses three Phase III clinical trials exploring the potential of PARP…
Related Articles
Long-term outcomes of PSA persistence after robotic prostatectomy
Alessandro Bertini, MD, IRCCS Ospedale San Raffaele, Milan, Italy & Henry Ford Health System, Detroit, MI, explores long-term survival and additional treatment rates in men…
The case for increased screening in prostate cancer
Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, describes the value of screening for prostate cancer, highlighting that an organized screening…
Updates in the 9th TNM classification of pleural mesothelioma
Isabelle Schmitt-Opitz, MD, University Hospital Zurich, Zurich, Switzerland, gives an overview of changes in the TNM9 classification for mesothelioma. The primary driver of the changes…
Barriers to clinical utilization of ADCs for lung cancer
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, comments on the challenges of implementing antibody-drug conjugates (ADCs) for lung cancer in the clinic. There is…
ADRIATIC: patterns of disease progression with durvalumab in LS-SCLC
Suresh Senan, MRCP, FRCR, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, discusses findings from the ADRIATIC study (NCT03703297) of durvalumab consolidation therapy in patients with…
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Increasing equity in lung screening in high-risk populations
David Baldwin, MD, FRCP, Nottingham City Hospital, Nottingham, United Kingdom, comments on the challenges and opportunities of improving lung cancer screening in high-risk populations, particularly…
Novel developments in treating IO-induced toxicities in lung cancer
Michel Obeid, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses the value of deep immune profiling in identifying biomarkers for major immunotherapy (IO)-induced toxicities…
Systemic immunotherapy for locally advanced cutaneous squamous carcinoma
Vishal Patel, MD, FAAD, FACMS, George Washington University (GW), Washington, DC, discusses the potential of systemic immunotherapy in the treatment of locally advanced cutaneous squamous…
Evolving approaches for mediastinal nodal involvement in NSCLC
Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, comments on the evolving field of mediastinal nodal involvement in patients with lung cancer, highlighting…